Traws Pharma Q1 net income $21.5M on warrant gain; cash $15.9M; CEO transition

Traws Pharma, Inc.

2025-Q1 EPS reported $2.09 revenue$57,000

Net income of $21.5M ($2.17 basic EPS) driven by $26.5M gain from warrant liability fair value change; revenue $57K.
Cash and equivalents $15.9M as of Mar 31, 2025, down from $21.3M; runway into Q1 2026.
Submitted FDA briefing package for tivoxavir marboxil (TXM) under Animal Rule; ratutrelvir briefing package planned Q2 2025.
Iain Dukes named Interim CEO after retirement of Werner Cautreels; Jack Stover appointed Chairman.
R&D expense $2.5M (+$0.6M YoY) on virology program; G&A $2.8M (-$0.6M YoY) on lower consulting fees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.